Abstract
Inflammatory pathways as well as angiogenic factors play a role in the pathogenesis of diabetic retinopathy. Thus research has been directed to evaluate the role of corticosteroids to treat diabetic retinopathy. The mechanism of action of corticosteroids and the potential complications are reviewed. Various routes of administration have been evaluated, including intravitreal, sub-Tenon, suprachoroidal, and topical therapy. Sustained-release corticosteroid devices have been formulated to extend their therapeutic effect and potentially reduce complications. Diabetic macular edema is the most common manifestation of diabetic retinopathy that is treated with corticosteroids. Data from prospective, multicenter randomized controlled studies are presented in detail. The chapter also reviews and discusses the effect of corticosteroid therapy on diabetic retinopathy progression, as well as used in combination therapy with anti-vascular endothelial growth factor agents.
| Original language | English |
|---|---|
| Title of host publication | Current Management of Diabetic Retinopathy |
| Publisher | Elsevier |
| Pages | 79-88 |
| Number of pages | 10 |
| ISBN (Electronic) | 9780323549493 |
| ISBN (Print) | 9780323484527 |
| DOIs | |
| State | Published - 2018 |
Keywords
- Corticosteroid
- Cytokines
- Diabetic macular edema
- Flucinoloneacetonide
- Inflammation
- Ozurdex
- Retisert
- Triamcinolone acetonide